Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oglemilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D known ✓ | Q08499 | 15/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 17/20 | 0.64 |
| ▸ | PDE4A known ✓ | P27815 | 14/20 | 0.64 |
| ▸ | PDE4C known ✓ | Q08493 | 13/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oglemilast SCHEMBL29413215 | 1.00 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Oglemilast SCHEMBL29369504 | 1.00 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Oglemilast SCHEMBL4030019 | 0.99 | PDE4D (0.98) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Oglemilast SCHEMBL4030005 | 0.99 | PDE4D (0.98) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL4035094 | 0.92 | PDE4D (0.85) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL4027253 | 0.91 | PDE4D (0.84) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL4029909 | 0.90 | PDE4D (0.81) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13777247 | 0.89 | PDE4D (0.81) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL4030622 | 0.89 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL4029693 | 0.88 | PDE4D (0.79) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 699 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565302-A1 | DRY POWDER INHALER | Chiesi Farmaceutici S.p.A. (IT) | 2025-06-11 | — | — | EP | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| US-20240042147-A1 | DRY POWDER INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-02-08 | — | — | US | claimed |
| WO-2024028388-A1 | DRY POWDER INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-02-08 | — | — | WO | claimed |
| US-11504332-B2 | Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof | VK RESEARCH ASSOCIATES INC. (US) | 2022-11-22 | — | — | US | claimed |
| US-20220304935-A1 | PHOSPHODIESTERASE-4 INHIBITOR COMBINATIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | VK Research Associates Inc | 2022-09-29 | — | — | US | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2008005955-A2 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | WO | claimed |
| US-20080009632-A1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | claimed |
| EP-1799632-A2 | PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE | Glenmark Pharmaceuticals S.A. (CH) | 2007-06-27 | — | — | EP | claimed |
| US-7223789-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-29 | — | — | US | claimed |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-10 | — | — | US | claimed |
| US-20060135779-A1 | Process for the preparation n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide | GLENMARK PHARMACEUTICALS S.A. (CH) | 2006-06-22 | — | — | US | claimed |
| WO-2006040652-A2 | PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-04-20 | — | — | WO | claimed |
| EP-1620429-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Glenmark Pharmaceuticals S.A. (CH) | 2006-02-01 | — | — | EP | claimed |
| US-20050027129-A1 | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS, INC. USA | 2005-02-03 | — | — | US | claimed |
| WO-2004089940-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (US) | 2004-10-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135779-A1 | Process for the preparation n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide | HCN4, REN, QDPR | PDE4D 378/4885PDE4B 696/4885PDE4A 1242/4885 |
| US-20050027129-A1 | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | PDE4A, PDE4B, PDE12 | PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20080009632-A1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | FDPS, DHPS, AADAC | PDE4D 1209/4885PDE4B 1634/4885PDE4A 2332/4885 |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDE4A, PDE4B, PDE12 | PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE4D 1677/4885PDE4B 1894/4885PDE4A 1073/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE4D 1677/4885PDE4B 1894/4885PDE4A 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.